Vinblastine suphate is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 868   Edition : 37  

  ►   Brandname : Cytoblastin, Velban
  ►  Strength :

A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : IV
Reference :-   Book : Martindale    Page : 868   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Antineoplastic IV Injection Care should be taken to avoid extravasation and the intravenous injection may be given over 1 minute into a freely-running infusion of sodium chloride 0.9% if preferred. The usual dose of vinblastine sulfate is about 6 mg/m2, not more than once every 7 days. Single doses starting at 3.7 mg/m2 and increasing at weekly intervals, over 4 weeks, to a usual maximum dose of 11.1 mg/m2 have been given; doses have been increased above this, but should not exceed 18.5 mg/m2. If a maintenance dose is required, it may be given every 7 days provided white cell counts permit.

Ref :-  Book : Martindale    Page : 868   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Antineoplastic IV 6 mg/m2 Injection

Ref :- Book : Martindale    Page : 869   Edition : 37  
►  Side Effect : Malaise, Weakness, Headache, Depression, Paraesthesia, Numbness, Loss of deep tendon reflexes, Peripheral neuropathies, Constipation, Adynamic ileus, Jaw pain, Convulsions, Dizziness, Nystagmus, Vertigo, Partial or total deafness, Skin reactions, Alopecia, Ischaemic cardiotoxicity, Hypertension, Dyspnoea, Bronchospasm, Bone and tumour pain, , Irritant to the skin and mucous membrane and extravasation may cause necrosis, cellulitis, and sloughing
Ref :-   Book : Martindale    Page : 868   Edition : 37.  

►  Drug Interaction : Drug interaction of Vinblastine suphate is with Phenytoin
Ref :-   Book : Martindale    Page : 868   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Use with drugs that inhibit cytochromes of the CYP3A subfamily may result in decreased metabolism of vinblastine and increased toxicity. Use with cisplatin has been reported to increase vinblastin plasma concentration. For a report of the possible contribution of vinblastine to reduced plasma concentrations of phenytoin.
Ref :-   Book : Martindale    Page : 868   Edition : 37.  

►  Contraindication : Intrathecal use of the vinca alkaloids is contra-indicated because of the likelihood of fatal neurotoxicity, It should not be injected into an extremity with impaired circulation because of an increased risk of thrombosis. It should be given with caution and at reduced dosage to patients with hepatic impairment
Ref :-   Book : Martindale    Page : 868   Edition : 37.  
  ►  Mechanism of Action :   Vinblastine sulfate is an antineoplastic agent that apparently acts by binding to the microtubular proteins of the spindle and arresting mitosis at the metaphase; it is thus specific for the M phase of the cell cycle. It also interferes with glutamate metabolism and possibly nucleic acid synthesis, and has some immunosuppressant activity.
Ref :-   Book : Martindale    Page : 868   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Vinca with same compound.   Tomato with Another pathway.  

  ►  Pathway with its reference as follows :-
  • lycopene have anticancer effect --- ( Al-Asmari, A., Albalawi, S., Athar, M., Khan, A., Al-Shahrani, H., & Islam, M. (2015). Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines. PLOS ONE, 10(8), e0135814. )
  • Vincristine arrests multiplication of cancerous cells --- (Kokate, c. & Purohit, A. (2016). pharmacognosy. nirali prakashan. )

  •   ►  URL --
  • .
  • .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Hepatic (Metabolism), Renal, Biliary, Faecal
    Ref :-   Book : Martindale    Page : 868   Edition : 37.  

    ►    Plasma Half-life :   Min value :-   25 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 868   Edition : 37.  

    ►    Peak Plasma Concentration :   Min value :-   NA    Max value :-   NA